Lobbying disclosures · Lobbying report
EBS: third_quarter 2026 lobbying report
Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical de
Follow EBS- Became public
- Oct 19, 2026, 4:27 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 9:47 AM EST
Why this is connected
Exact legal-name match: Emergent BioSolutions Inc. (https://www.sec.gov/Archives/edgar/data/1367644/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/5c334800-1d2d-41fa-8b66-cfa3d65ba082/","filing_uuid":"5c334800-1d2d-41fa-8b66-cfa3d65ba082","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/5c334800-1d2d-41fa-8b66-cfa3d65ba082/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Mike Nielsen","dt_posted":"2026-10-19T16:27:48-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1307 New York Ave., NW Suite 600","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":76992,"url":"https://lda.gov/api/v1/registrants/76992/","house_registrant_id":36118,"name":"CGCN GROUP, LLC","description":"Public Affairs Consultants","address_1":"1307 New York Ave., NW Suite 600","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE CLARK","contact_telephone":"+1 202-628-0028","dt_updated":"2026-07-12T16:09:24.002258-04:00"},"client":{"id":56107,"url":"https://lda.gov/api/v1/clients/56107/","client_id":56107,"name":"EMERGENT BIOSOLUTIONS INC.","general_description":"Biopharmaceutical Company","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-05-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143752,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARTHA","nickname":null,"middle_name":"BEATRICE","last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142906,"prefix":null,"prefix_display":null,"first_name":"JILL","nickname":null,"middle_name":null,"last_name":"HAMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145578,"prefix":null,"prefix_display":null,"first_name":"JA'RON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154390,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"GILBERT","suffix":null,"suffix_display":null},"covered_position":"(4) Intern, Rep. George Holding, Aug. 2016-Dec 2016; Intern, Sen. Richard Burr, June 2016-July 2016","new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"DIS","general_issue_code_display":"Disaster Planning/Emergencies","description":"Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143752,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARTHA","nickname":null,"middle_name":"BEATRICE","last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142906,"prefix":null,"prefix_display":null,"first_name":"JILL","nickname":null,"middle_name":null,"last_name":"HAMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145578,"prefix":null,"prefix_display":null,"first_name":"JA'RON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154390,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"GILBERT","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143752,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARTHA","nickname":null,"middle_name":"BEATRICE","last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142906,"prefix":null,"prefix_display":null,"first_name":"JILL","nickname":null,"middle_name":null,"last_name":"HAMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145578,"prefix":null,"prefix_display":null,"first_name":"JA'RON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154390,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"GILBERT","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143752,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARTHA","nickname":null,"middle_name":"BEATRICE","last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142906,"prefix":null,"prefix_display":null,"first_name":"JILL","nickname":null,"middle_name":null,"last_name":"HAMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145578,"prefix":null,"prefix_display":null,"first_name":"JA'RON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154390,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"GILBERT","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in EBS
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Jan 10, 2025$1K–$15K
Rep. Steve Cohen (D-TN-9)
Sold Emergent BioSolutions EBS
$1K–$15K · Traded Dec 11, 2024 · disclosed Jan 10, 2025
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.